BL0020 for lung cancer that changed form after targeted therapy
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, BL0020, for people whose non-small cell lung cancer with an EGFR mutation has turned into small cell lung cancer after EGFR-targeted therapy. It aims to see if BL0020 is safe and effective for this specific change.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You were first diagnosed with EGFR-mutated non-small cell lung cancer, and it later changed to small cell lung cancer after taking an EGFR-targeted drug.
- For the small cell lung cancer, you have either only tried platinum chemotherapy or have not had any treatment yet.
- You are able to take care of yourself (ECOG score 0 or 1).
- You do not have active or untreated brain metastases that cause symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (BL0020 and Toripalimab) in patients whose small cell lung cancer has come back after initial chemotherapy treatment. The goal is to see if this combination is safe and can help control the cancer.
This trial tests a new drug (tarlatamab) combined with chemotherapy and immunotherapy for people whose lung cancer has changed from one type (adenocarcinoma) to small cell lung cancer after treatment with EGFR targeted therapy. The goal is to see if this combination is safe and works well.
This trial tests a new targeted drug (PLB1004) combined with two chemotherapy drugs for people with a specific EGFR gene change in their non-small cell lung cancer. The goal is to see if this combination works better than current treatments, both for advanced cancer and for cancer that can be surgically removed.
This trial tests a new drug, BL-M09D1, in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the cancer.
This trial tests a new drug combination—BL-B01D1 plus a PD-1 immunotherapy—for people who have just been diagnosed with extensive-stage small cell lung cancer and have not had any prior treatment for it. The goal is to see if this combination can help shrink or control the cancer better than standard therapy.
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
Hear when a new Small Cell Carcinoma of Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.